Genomic Test Helps Estimate Risk of Prostate Cancer Metastasis ...

Prostate Cancer Tests for Diagnosis & Screening

If a biopsy sample is found to contain cancer, the pathologist analyzing the specimen takes a deeper look at the cancer cells to determine how ...

Genetic Testing for Prostate Cancer Treatment - Myriad Genetics

There are a few different types of tests to help you better understand your prostate cancer treatment options. Prolaris® Prostate Cancer Prognostic Test is a ...

Genetic Testing For Prostate Cancer | BRCA - YouTube

... Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment ...

Genomic Prostate Score Results - PC Markers

The test looks at the activation of 17 specific genes (using specialized lab tests using your prostate cancer positive tissue taken during your previous biopsy) ...

The 17-Gene Genomic Prostate Score Test Is Prognostic for ...

The Oncotype DX Genomic Prostate Score (GPS) is a 17-gene assay that evaluates the expression of 12 cancer-related genes and 5 reference genes ...

When to Use Somatic Tumor Testing in Prostate Cancer

All patients with metastatic prostate cancer are eligible for somatic tumor genetic (DNA) testing to look for mutations in the cancer that may be targetable ...

Genetic Testing and Counselling in Prostate Cancer | PCFA

You may have also have another type of testing called genomic testing, to check how your prostate cancer might behave (whether it might grow and spread and how ...

Prostate Cancer Nomograms

This tool is designed to calculate the likelihood of having high-grade prostate cancer in men who have been considered eligible for prostate biopsy by a ...

Prostate Cancer and Genetic Testing - WebMD

Genetic mutations passed down through families cause up to 12% of prostate cancers. Genetic testing could provide information that changes ...

4Kscore (Prostate-Specific Kallikrein) - ARUP Laboratories

ARUP offers FDA approved Prostate- Specific Kallikrein, 4Kscore (test code 2014059) to help determine the risk of prostate cancer.

Incorporating Genomic Testing for Prostate Cancer into Your Practice

Mounting evidence suggests genomic tests are useful through all stages of prostate cancer diagnosis and treatment. “Incorporating Genomic Testing for Prostate ...

4Kscore® Prostate Test Patients

The 4Kscore® Test result assesses your probability of aggressive prostate cancer if a biopsy were performed and has been shown to categorize long-term risk of ...

Cancer Risks in People with an ATM Mutation

People with an inherited mutation in the ATM gene have an increased risk for certain types of cancer. Read more about these cancer risks.

Validation of a Genomic Classifier that Predicts Metastasis Following ...

Patients with metastasis at diagnosis or any prior treatment for prostate cancer were excluded from analysis. A 20% random sampling created a ...

Genomic Test Predicts Metastasis, Mortality in Prostate Cancer

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for ...

Metastatic Stage 4 Prostate Cancer: Symptoms, Treatment, Prognosis

PSA stands for prostate-specific antigen, which may be high in men who have prostate cancer. PSA tests are used not only for the initial cancer ...

Prostate cancer genetic testing and genetic counseling - YouTube

Mutations in BRCA, ATM, Lynch syndrome genes and others increase the risk of prostate cancer. This session will cover the latest research on ...

Prostate cancer - Wikipedia

Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is ...

Riskguard® test - Exact Sciences

Take the Riskguard® hereditary cancer test. It checks for inherited genetic changes that can cause an increased risk for certain cancers.

New Data Validate Clinical Utility of Genomic Classifier Test to Help ...

These findings represent the first high-level evidence of any genomic classifier in intermediate-risk prostate cancer and demonstrate that the ...